FDA To Launch Pharmacogenomics Website, Issue Guidance In March
This article was originally published in The Gray Sheet
Executive Summary
FDA will publish its final guidance on voluntary pharmacogenomic data submissions in March, Office of Clinical Pharmacology & Biopharmaceutics Director Lawrence Lesko told the Drug Information Association meeting in Lisbon, Portugal March 9
You may also be interested in...
Diagnostic Makers Seek Clarification On Biomarker Validation Standards
FDA should elucidate biomarker terminology in finalizing its guidance on pharmacogenomic data submissions, Genzyme says in comments to the agency
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.